Atezolizumab: beside a new treatment under test

279 studies: a new drug, cell therapy or vaccine is what the study tests. Page 3 of 3. Open to participants first (64), then studies with results posted, then the rest; newest registration first within each.

• Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without ChemotherapyTerminatedNCT04911166Phase 1Report a problem
• Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid TumorsCompletedNCT04896697Phase 1/2Report a problem
• A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid TumorsCompletedNCT04857138Phase 1Report a problem
• A MultIceNTER Phase I Peptide VaCcine Trial for the Treatment of H3-Mutated GliomasActive, not recruitingNCT04808245Phase 1Report a problem
• A Study of KF-0210 in Advanced Solid Tumors PatientsCompletedNCT04713891Phase 1Report a problem
• Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).Status unknownNCT04690686Phase 2Report a problem
• A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast CancerCompletedNCT04584112Phase 1Report a problem
• LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung CancerActive, not recruitingNCT04560972Phase 1Report a problem
• A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)Active, not recruitingNCT04524871Phase 1/2Report a problem
• A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)Active, not recruitingNCT04471727Phase 1/2Report a problem
• Study to Investigate DRP-104 in Adults With Advanced Solid TumorsTerminatedNCT04471415Phase 1/2Report a problem
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingNCT04449874Phase 1Report a problem
• A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid TumorsActive, not recruitingNCT04440735Phase 1/2Report a problem
• A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung CancerTerminatedNCT04432207Phase 1Report a problem
• Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical CancerCompletedNCT04405349Phase 2Report a problem
• A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).TerminatedNCT04404140Phase 1Report a problem
• A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung CancerTerminatedNCT04308785Phase 2Report a problem
• A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid TumorsTerminatedNCT04303858Phase 1Report a problem
• A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung CancerWithdrawnNCT04267237Phase 2Report a problem
• An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT04250155Phase 1Report a problem
• BDB001-102: Open Label Dose Escalation of BDB001 in Combination w AtezolizumabCompletedNCT04196530Phase 1Report a problem
• Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingNCT04185883Phase 1Report a problem
• WaKING: Wnt and checKpoint INhibition in Gastric CancerActive, not recruitingNCT04166721Phase 1/2Report a problem
• Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With SurgeryActive, not recruitingNCT04161755Phase 1Report a problem
• D2C7-IT With Atezolizumab for Recurrent GliomasCompletedNCT04160494Phase 1Report a problem
• IN10018 Monotherapy and Combination Therapy for Metastatic MelanomaCompletedNCT04109456Phase 1Report a problem
• A Window-of-opportunity Study of Pelareorep in Early Breast CancerTerminatedNCT04102618Early Phase 1Report a problem
• Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid TumorsCompletedNCT04096638Phase 1Report a problem
• Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid TumorsCompletedNCT04084951Phase 1Report a problem
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1Report a problem
• Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate CancerWithdrawnNCT04020094Phase 2Report a problem
• Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant GliomaWithdrawnNCT03973879Phase 1/2Report a problem
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With AtezolizumabWithdrawnNCT03973333Phase 1/2Report a problem
• Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell CarcinomaActive, not recruitingNCT03961698Phase 2Report a problem
• Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBCTerminatedNCT03952325Phase 2Report a problem
• Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)CompletedNCT03946358Phase 2Report a problem
• Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid TumorsActive, not recruitingNCT03915678Phase 2Report a problem
• Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedNCT03892525Phase 1Report a problem
• A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaTerminatedNCT03866239Phase 1Report a problem
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsActive, not recruitingNCT03845166Phase 1Report a problem
• FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid TumorsCompletedNCT03841110Phase 1Report a problem
• Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic CancerStatus unknownNCT03835949Phase 1Report a problem
• Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric CancerWithdrawnNCT03818997Phase 2Report a problem
• Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1TerminatedNCT03721679Phase 1/2Report a problem
• A Trial of Ipatasertib in Combination With AtezolizumabActive, not recruitingNCT03673787Phase 1/2Report a problem
• PRS-343 in Combination With Atezolizumab in HER2-Positive Solid TumorsCompletedNCT03650348Phase 1Report a problem
• This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated CancersTerminatedNCT03618953Phase 1Report a problem
• Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknownNCT03544723Phase 2Report a problem
• An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03533283Phase 1/2Report a problem
• Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3Report a problem
• Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and CarboplatinWithdrawnNCT03498222Phase 1Report a problem
• Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerCompletedNCT03438318Phase 1Report a problem
• Pre-operative Immunotherapy Combination Strategies in Breast CancerCompletedNCT03395899Phase 2Report a problem
• A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT03369964Phase 1Report a problem
• Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial CancerCompletedNCT03359239Phase 1Report a problem
• A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast CancerTerminatedNCT03292172Phase 1Report a problem
• A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic TumorsCompletedNCT03289962Phase 1Report a problem
• QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2Report a problem
• Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial CarcinomaActive, not recruitingNCT03179943Phase 2Report a problem
• Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)CompletedNCT03063762Phase 1Report a problem
• Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or RelapsedActive, not recruitingNCT02935361Phase 1/2Report a problem
• A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)CompletedNCT02892318Phase 1Report a problem
• Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis FungoidesTerminatedNCT02890368Phase 1Report a problem
• ACTolog in Patients With Solid CancersCompletedNCT02876510Phase 1Report a problem
• Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic TumorsCompletedNCT02794571Phase 1Report a problem
• LOAd703 Oncolytic Virus Therapy for Pancreatic CancerCompletedNCT02705196Phase 1/2Report a problem
• Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCompletedNCT02655822Phase 1Report a problem
• A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid TumorsCompletedNCT02650713Phase 1Report a problem
• A Study of Varlilumab and Atezolizumab in Patients With Advanced CancerTerminatedNCT02543645Phase 1Report a problem
• A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)CompletedNCT02500407Phase 1/2Report a problem
• A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02471846Phase 1Report a problem
• In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®CompletedNCT02423863Phase 2Report a problem
• A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT02410512Phase 1Report a problem
• A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedNCT02350673Phase 1Report a problem
• A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid TumorsCompletedNCT02323191Phase 1Report a problem
• A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid TumorsCompletedNCT02304393Phase 1Report a problem
• A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedNCT02298153Phase 1Report a problem
• A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid TumorsCompletedNCT01688206Phase 1Report a problem
• A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent StudiesActive, not recruitingNCT00781612Phase 2Report a problem

← Atezolizumab